Biorchestra Co. Ltd

Drug delivery technologies will continue to be a main theme for the Korean biopharma industry in 2024. Amid a tougher environment to develop innovative therapies, more companies may prioritize develop

South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment. Although most

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Junshi Allies With Rxilient On JV

The challenges and opportunities of running a bioventure depend on which country you’re based in and which market you’re focused on. And it matters too for large pharmaceutical firms in search for the